To appraise the clinical and cost effectiveness of vemurafenib within its marketing authorisation for adjuvant treatment of resected BRAF V600 mutation-positive melanoma with high risk of recurrence.
The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
 
Status Suspended
Process STA
ID number 1250

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
18 October 2017 Suspended, The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
18 October 2017 The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
29 August 2017 - 26 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
28 August 2017 Draft scope documents
19 September 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance